Citations to this article
Citation Information: J Clin Invest. 2021;131(24):e155476. https://doi.org/10.1172/JCI155476.
Abstract
Immune checkpoint blockade (ICB) therapies are standard of care for the treatment of many solid tumors. While some patients with cancer experience exceptional and long-term responses, intrinsic and acquired mechanisms of resistance limit the clinical efficacy of ICBs. In addition, ICBs can elicit life-threatening side effects. Alternative options that can increase ICB responses without added toxicities are needed. In this issue of the JCI, Chakraborty et al. explored the role of estrogen receptor α (ERα) in modulating ICB activity. Using transcriptomics and preclinical melanoma models, the authors show that ERα signaling in tumor-associated macrophages contributed to an immune-suppressive state within the tumor microenvironment (TME) by promoting CD8+ T cell dysfunction and exhaustion. Further, in murine melanoma models, the addition of fulvestrant, a selective estrogen receptor downregulator (SERD) approved for the treatment of breast cancer, enhanced the antitumor effects of ICB. These results provide a rationale for human trials to test the combination of antiestrogens with ICBs.
Authors
James M. Rae, Marc E. Lippman
Citations to this article (10)
| Title and authors | Publication | Year |
|---|---|---|
|
Sex bias in tumor immunity: insights from immune cells
Tao X, Wang Y, Xiang B, Hu D, Xiong W, Liao W, Zhang S, Liu C, Wang X, Zhao Y |
Theranostics | 2025 |
|
Harnessing the Stem Cell Niche in Regenerative Medicine: Innovative Avenue to Combat Neurodegenerative Diseases.
Velikic G, Maric DM, Maric DL, Supic G, Puletic M, Dulic O, Vojvodic D |
International journal of molecular sciences | 2024 |
|
Towards targeting the breast cancer immune microenvironment.
Harris MA, Savas P, Virassamy B, O'Malley MMR, Kay J, Mueller SN, Mackay LK, Salgado R, Loi S |
Nature reviews. Cancer | 2024 |
|
LINC00173 silence and estrone supply suppress ER+ breast cancer by estrogen receptor α degradation and LITAF activation
Xie Y, Shan M, Yu J, Du Y, Wu C, Liu S, Li J, Xiao Y, Yan Y, Li N, Qin J, Lan L, Wang Y |
Cancer Science | 2024 |
|
EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer
Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV |
2023 | |
|
Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems
Fu Z, Zhang X, Gao Y, Fan J, Gao Q |
Clinical and Translational Medicine | 2023 |
|
The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer
Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV |
Cancer research | 2023 |
|
Deficiency of PSRC1 accelerates atherosclerosis by increasing TMAO production via manipulating gut microbiota and flavin monooxygenase 3.
Luo T, Guo Z, Liu D, Guo Z, Wu Q, Li Q, Lin R, Chen P, Ou C, Chen M |
Gut microbes | 2022 |
|
Genomic mapping of copy number variations influencing immune response in breast cancer.
López-Cade I, García-Barberán V, Cabañas Morafraile E, Díaz-Tejeiro C, Saiz-Ladera C, Sanvicente A, Pérez Segura P, Pandiella A, Győrffy B, Ocaña A |
Frontiers in Oncology | 2022 |
|
Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy
Tan L, Tondo-Steele K, Foster C, McIlwain C, Bolland DE, Crawford HC, Sciallis A, McLean K |
Cancers | 2022 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)